AI drug discovery startup Earendil Labs is considering going public in Hong Kong to raise as much as $500 million, Bloomberg News reported Friday, citing people familiar with the matter.
The firm is working with CICC and Morgan Stanley on a potential listing, the report said.
Based in Delaware, Earendil is an affiliate of Beijing-based Helixon Therapeutics, according to the report.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments